Evidence map›Paper›PMID 24262762›Full record

Trial reportThe American journal of cardiology2014

Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study).

Benjamin Wallace Van Tassell, Ross Arena, Giuseppe Biondi-Zoccai, Justin McNair Canada, Claudia Oddi, Nayef Antar Abouzaki, Arehzo Jahangiri, Raquel Appa Falcao, Michael Christopher Kontos, Keyur Bharat Shah and 3 more

Open access · greenAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 3 pooled it
47.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 3 syntheses or guidelines pooled it, 273 citations in OpenAlex.

  1. Immunology of heart failure with preserved ejection fraction.Expert review of clinical immunology · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Benjamin Wallace Van Tassell *Virginia Commonwealth University, VCU Pauley Heart Center and Victoria Johnson Research Laboratories, Richmond, VA, USA.
Ross Arena *
Giuseppe Biondi-Zoccai
Justin McNair CanadaVirginia Commonwealth University, VCU Pauley Heart Center and Victoria Johnson Research Laboratories, Richmond, VA, USA.
Claudia OddiVirginia Commonwealth University, VCU Pauley Heart Center and Victoria Johnson Research Laboratories, Richmond, VA, USA.
Nayef Antar AbouzakiVirginia Commonwealth University, VCU Pauley Heart Center and Victoria Johnson Research Laboratories, Richmond, VA, USA.
Arehzo JahangiriVirginia Commonwealth University, VCU Pauley Heart Center and Victoria Johnson Research Laboratories, Richmond, VA, USA.
Raquel Appa FalcaoVirginia Commonwealth University, VCU Pauley Heart Center and Victoria Johnson Research Laboratories, Richmond, VA, USA.
Michael Christopher KontosVirginia Commonwealth University, VCU Pauley Heart Center and Victoria Johnson Research Laboratories, Richmond, VA, USA.
Keyur Bharat ShahVirginia Commonwealth University, VCU Pauley Heart Center and Victoria Johnson Research Laboratories, Richmond, VA, USA.
Norbert Felix VoelkelVirginia Commonwealth University, VCU Pauley Heart Center and Victoria Johnson Research Laboratories, Richmond, VA, USA.
Charles Anthony Dinarello
Antonio AbbateVirginia Commonwealth University, VCU Pauley Heart Center and Victoria Johnson Research Laboratories, Richmond, VA, USA.
Virginia Commonwealth University · USUniversity of Colorado Denver · USUniversity of Illinois Chicago · US

Funding

Center for Clinical and Translational ResearchUL1TR000058 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2012 to 2015
$12.5M
Yeast-based HTS Assay Technologies for ProteasesR01AI015614 · NIAID · UNIVERSITY OF COLORADO DENVER · PI DINARELLO, CHARLES ANTHONY · 1985 to 2025
$8.5M
Center for Clinical and Translational ResearchKL2RR031989 · NCRR · VIRGINIA COMMONWEALTH UNIVERSITY · PI CLORE, JOHN N. · 2010 to 2011
$995k
Pathogenesis of Fever in ManR56AI015614 · NIAID · UNIVERSITY OF COLORADO DENVER · PI DINARELLO, CHARLES ANTHONY · 2016 to 2016
$311k
PATHOGENESIS OF FEVER IN HUMANSR37AI015614 · NIAID · UNIVERSITY OF COLORADO DENVER · PI DINARELLO, CHARLES ANTHONY · 1988 to 1998
–
NCATS NIH HHS UL1 TR000058NCRR NIH HHS KL2 RR031989NCRR NIH HHS KL2RR031989NIAID NIH HHS AI-15614NIAID NIH HHS R01 AI015614NIAID NIH HHS R56 AI015614
6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome of exercise intolerance due to impaired myocardial relaxation and/or increased stiffness. Patients with HFpEF often show signs of chronic systemic inflammation, and experimental studies have shown that interleukin-1 (IL-1), a key proinflammatory cytokine, impairs myocardial relaxation. The aim of the present study was to determine the effects of IL-1 blockade with anakinra on aerobic exercise capacity in patients with HFpEF and plasma C-reactive protein (CRP) >2 mg/L (reflecting increased IL-1 activity). A total of 12 patients were enrolled in a double-blind, randomized, placebo-controlled, crossover trial and assigned 1:1 to receive 1 of the 2 treatments (anakinra 100 mg or placebo) for 14 days and an additional 14 days of the alternate treatment (placebo or anakinra). The cardiopulmonary exercise test was performed at baseline, after the first 14 days, and after the second 14 days of treatment. The placebo-corrected interval change in peak oxygen consumption was chosen as the primary end point. All 12 patients enrolled in the present study and receiving treatment completed both phases and experienced no major adverse events. Anakinra led to a statistically significant improvement in peak oxygen consumption (+1.2 ml/kg/min, p = 0.009) and a significant reduction in plasma CRP levels (-74%, p = 0.006). The reduction in CRP levels correlated with the improvement in peak oxygen consumption (R = -0.60, p = 0.002). Three patients (25%) had mild and self-limiting injection site reactions. In conclusion, IL-1 blockade with anakinra for 14 days significantly reduced the systemic inflammatory response and improved the aerobic exercise capacity of patients with HFpEF and elevated plasma CRP levels.

Indexed as

AdultAgedAntirheumatic AgentsCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodExerciseExercise ToleranceFemaleFollow-Up StudiesHeart FailureHumansInterleukin-1Interleukin 1 Receptor Antagonist ProteinMaleMiddle AgedAntirheumatic AgentsInterleukin-1Interleukin 1 Receptor Antagonist Protein

Identifiers

PMID24262762
PMCPMC4899612
OpenAlexW2171449411

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.